BE2014C030I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C030I2
BE2014C030I2 BE2014C030C BE2014C030C BE2014C030I2 BE 2014C030 I2 BE2014C030 I2 BE 2014C030I2 BE 2014C030 C BE2014C030 C BE 2014C030C BE 2014C030 C BE2014C030 C BE 2014C030C BE 2014C030 I2 BE2014C030 I2 BE 2014C030I2
Authority
BE
Belgium
Application number
BE2014C030C
Other languages
French (fr)
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C030(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of BE2014C030I2 publication Critical patent/BE2014C030I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE2014C030C 2002-05-08 2014-05-12 BE2014C030I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10220570A DE10220570A1 (en) 2002-05-08 2002-05-08 Carbamate-substituted pyrazolopyridines

Publications (1)

Publication Number Publication Date
BE2014C030I2 true BE2014C030I2 (en) 2022-08-09

Family

ID=29265155

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C030C BE2014C030I2 (en) 2002-05-08 2014-05-12

Country Status (40)

Country Link
US (1) US7173037B2 (en)
EP (1) EP1506193B9 (en)
JP (1) JP4455321B2 (en)
KR (1) KR101011864B1 (en)
CN (1) CN1330649C (en)
AR (1) AR039789A1 (en)
AT (1) ATE330957T1 (en)
AU (1) AU2003233061B2 (en)
BE (1) BE2014C030I2 (en)
BR (1) BRPI0309855B8 (en)
CA (1) CA2485143C (en)
CU (1) CU23453B7 (en)
CY (2) CY1105579T1 (en)
DE (2) DE10220570A1 (en)
DK (1) DK1506193T6 (en)
DO (1) DOP2003000639A (en)
EC (1) ECSP045414A (en)
ES (1) ES2268363T3 (en)
FI (1) FI1506193T6 (en)
FR (1) FR14C0032I2 (en)
GT (1) GT200300101A (en)
HR (1) HRP20041166B1 (en)
IL (1) IL164958A (en)
LT (1) LTC1506193I2 (en)
LU (1) LU92419I2 (en)
MX (1) MXPA04011003A (en)
MY (1) MY136841A (en)
NL (1) NL300659I2 (en)
NO (3) NO329105B1 (en)
NZ (1) NZ536417A (en)
PE (1) PE20040197A1 (en)
PL (1) PL214985B1 (en)
PT (1) PT1506193E (en)
RU (1) RU2339638C9 (en)
SI (1) SI1506193T2 (en)
TW (1) TWI282792B (en)
UA (1) UA78314C2 (en)
UY (1) UY27793A1 (en)
WO (1) WO2003095451A1 (en)
ZA (1) ZA200408925B (en)

Families Citing this family (328)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110747A1 (en) * 2001-03-07 2002-09-12 Bayer Ag Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
CN1805938B (en) * 2003-06-17 2010-06-16 艾尼纳制药公司 Benzazepine derivatives for the treatment of 5HT2C receptor-related diseases
EP1644347A1 (en) * 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES
PE20050483A1 (en) 2003-10-31 2005-08-25 Arena Pharm Inc TETRAZOLE DERIVATIVES OF FORMULA (I), ITS PHARMACEUTICAL COMPOSITIONS AND PROCESSES TO PRODUCE PHARMACEUTICAL COMPOSITIONS
DE10351903A1 (en) * 2003-11-06 2005-06-09 Bayer Healthcare Ag New combination
DE102004042607A1 (en) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituted phenylaminothiazoles and their use
US20080138444A1 (en) * 2004-10-05 2008-06-12 Bayer Healthcare Ag Method For Treating Bronchoconstriction and Pulmonary Vaso-Constriction
SG158168A1 (en) 2004-12-23 2010-01-29 Arena Pharm Inc 5ht2c receptor modulator compositions and methods of use
DE102005031575A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Use of soluble guanylate cyclase activators to promote wound healing
DE102005031576A1 (en) * 2005-07-06 2007-01-25 Bayer Healthcare Ag Use of benzoic acid, pyrimidine and benzamide compounds, as activators of soluble guanylate cyclase for the treatment or prevention of reperfusion injury,
DE102005047945A1 (en) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Use of soluble guanylate cyclase activators for the treatment of Raynaud's phenomena
DE102005047946A1 (en) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases
DE102006042143A1 (en) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Novel substituted bipyridine derivatives and their use
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102006044696A1 (en) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-cyano-5-thiazaheteroaryl-dihydropyridines and their use
DE102006054757A1 (en) * 2006-11-21 2008-05-29 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102006056739A1 (en) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituted 4-amino-3,5-dicyano-2-thiopyridines and their use
DE102006056740A1 (en) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
DE102007009494A1 (en) 2007-02-27 2008-08-28 Bayer Healthcare Ag New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke
DE102007015034A1 (en) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituted dicarboxylic acids and their use
DE102007015035A1 (en) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituted dibenzoic acid derivatives and their use
DE102007019691A1 (en) 2007-04-26 2008-10-30 Bayer Healthcare Ag Use of acyclically substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
DE102007019690A1 (en) 2007-04-26 2008-10-30 Bayer Healthcare Ag Use of cyclic substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
WO2008138483A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
DE102007026392A1 (en) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Solutions for the perfusion and preservation of organs and tissues
DE102007027799A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted furopyrimidines and their use
DE102007027800A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted bicyclic heteroaryl compounds and their use
DE102007035367A1 (en) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituted aryloxazoles and their use
DE102007036076A1 (en) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid Produgs and their use
DE102007042754A1 (en) * 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituted 6-phenyl-nicotinic acids and their use
DE102007051762A1 (en) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituted pyrrolotriazines and their use
DE102007054786A1 (en) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituted Furopyrimidines and their Use
DE102007061764A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
DE102007061757A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 2-phenylpyrimidine-5-carboxylic acids and their use
DE102008022521A1 (en) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use
DE102007061766A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system
DE102007061763A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted azabicyclic compounds and their use
DE102008052013A1 (en) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft New 4-(4-cyano-2-thioaryl)dihydropyrimidinone compounds are neutrophil elastase inhibitors useful to treat or prevent e.g. pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute lung injury, or cystic fibrosis
DE102007061756A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituted 4-aminopyrimidine-5-carboxylic acids and their use
DE102008007400A1 (en) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituted furans and their use
CN102015591B (en) * 2008-03-04 2014-01-29 艾尼纳制药公司 Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-choro-i-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
DE102008013587A1 (en) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituted dicyanopyridines and their use
DE102008018675A1 (en) 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclic substituted carboxylic acid derivatives and their use
RU2010150451A (en) * 2008-05-10 2012-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) RHC STIMULANTS AND THEIR COMBINATIONS FOR TREATMENT OF HEARING DISORDERS
CA2726020C (en) * 2008-05-29 2016-08-16 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituted dicyanopyridines and use thereof
DE102008030207A1 (en) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl-indoles and their use
DE102008030206A1 (en) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-cyanoalky- and 3-hydroxyalkyl-indoles and their use
DE102008039082A1 (en) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclic-substituted 5-aminopyrazoles and their use
DE102008039083A1 (en) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituted 5-aminopyrazoles and their use
DE102008054205A1 (en) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Use of helium-oxygen gas mixtures for the treatment of pulmonary arterial hypertension
AU2009322836B2 (en) * 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008060967A1 (en) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituted phenylsulfonyltriazolones and their use
DE102008062566A1 (en) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Amino acid ester prodrugs and their use
DE102008062567A1 (en) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid prodrugs and their use
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
DE102009004197A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclic fused diaryldihydropyrimidine derivatives and their use
EP2387404B1 (en) * 2009-01-17 2014-06-25 Bayer Intellectual Property GmbH Sgc stimulators and activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
DE102009006602A1 (en) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
DE102009012314A1 (en) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclic substituted alkylcarboxylic acids and their use
DE102009013642A1 (en) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted phenylalanine derivatives and their use
DE102010001064A1 (en) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
DE102009016553A1 (en) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use
DE102009028929A1 (en) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102009046115A1 (en) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituted 3-phenylpropanoic acids and their use
UY33041A (en) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
PH12012501023A1 (en) 2009-11-27 2014-12-19 Adverio Pharma Gmbh Method for producing methyl - {4, 6-diamino -2-[1- (2-fluorobenzyl) -1h- pyrazolo [3,4-b] pyridino -3-yl] pyrimidino -5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
UY33040A (en) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft NEW FORMS POLYMORPHES OF {4,6DIAMINO-2- [1- (2-FLUOROBENCIL-1H-PIRAZOL [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} METHYL CARBAMATE
WO2011073118A1 (en) 2009-12-14 2011-06-23 Bayer Schering Pharma Aktiengesellschaft Novel solvates of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
SI2531187T1 (en) 2010-02-05 2016-01-29 Adverio Pharma Gmbh sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
EA023221B1 (en) 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх Bis-aryl-bonded aryltriazolones, processes for preparation thereof, use thereof, medicament based thereon and double v1/v2 receptor antagonist
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010020553A1 (en) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituted 8-alkoxy-2-aminotetralin derivatives and their use
SI2576548T1 (en) * 2010-05-26 2015-11-30 Adverio Pharma Gmbh THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)
DE102010021637A1 (en) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
UA107112C2 (en) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. ACTIVATORS OF SOLUTION GUANILATE CYCLES
KR20130112848A (en) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. Processes for the preparation of 5-ht2c receptor agonists
DE102010030187A1 (en) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease
EP2687210A1 (en) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Stimulators and activators of soluble guanylate cyclase for use in the treatment of sickle cell anaemia and preservation of blood substitutes
DE102010030688A1 (en) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituted dicyanopyridines and their use
DE102010031148A1 (en) 2010-07-09 2012-01-12 Bayer Schering Pharma Ag New 1-(2-fluoro-benzyl)-1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease
PE20130779A1 (en) 2010-07-09 2013-06-21 Bayer Ip Gmbh PYRIMIDINES AND CONDENSED TRIAZINES AND THEIR USE
DE102010031149A1 (en) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease
DE102011007891A1 (en) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft New ring-fused 4-aminopyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease and renal insufficiency
DE102011003315A1 (en) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful for treating and/or preventing e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease, and fibrotic disorder
EP2590987B1 (en) 2010-07-09 2016-03-09 Bayer Intellectual Property GmbH Condensed 4-aminopyrimidines and their use as stimulators of soluble guanylate cyclase
EP2593452B1 (en) 2010-07-14 2017-01-18 Novartis AG Ip receptor agonist heterocyclic compounds
DE102010031667A1 (en) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituted methyl pyrimidin-5-ylcarbamates and their use
DE102010031665A1 (en) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituted oxazolidinones and oxazinones and their use
DE102010031666A1 (en) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Carbamate-substituted diaminopyrimidines and their use
KR20140091458A (en) 2010-09-01 2014-07-21 아레나 파마슈티칼스, 인크. Administration of lorcaserin to individuals with renal impairment
KR20130138770A (en) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. Salts of lorcaserin with optically active acids
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
JP2013536859A (en) 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド Non-hygroscopic salt of 5-HT2C agonist
DE102010040187A1 (en) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituted N-phenethyl-triazolone acetamides and their use
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
DE102010040924A1 (en) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituted phenylacet and phenylpropanamides and their use
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
DE102010043380A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituted carbamates and their use
CN102485724B (en) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
WO2012076466A2 (en) 2010-12-07 2012-06-14 Bayer Pharma Aktiengesellschaft Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
DE102010062544A1 (en) 2010-12-07 2012-06-14 Bayer Schering Pharma Aktiengesellschaft New substituted 1-benzylcycloalkylcarboxylic acid compounds are soluble guanylate cyclase activators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertension, pulmonary hypertension and vascular disease
DE102011006974A1 (en) 2011-04-07 2012-10-11 Bayer Pharma Aktiengesellschaft New substituted 1-benzylcycloalkylcarboxylic acid compounds are soluble guanylate cyclase activators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertension, ischemia and vascular disease
DE102011075399A1 (en) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
DE102012200356A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
DE102012200357A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
DE102011007890A1 (en) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
ES2583086T3 (en) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pyrazolopyridines substituted with fluoroalkyl and their use
CN103649093B (en) 2011-05-06 2017-07-07 拜耳知识产权有限责任公司 Substituted imidazopyridine and Imidazopyridazine and application thereof
DE102011075398A1 (en) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituted imidazopyridazines and their use
CA2836202A1 (en) 2011-05-30 2012-12-06 Astellas Pharma Inc. Imidazopyridine compounds
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
DE102011078715A1 (en) 2011-07-06 2013-01-10 Bayer Pharma AG New substituted pyrazolo-pyridine derivatives useful for treating and/or prophylaxis of e.g. congestive heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, and fibrotic diseases
DE102012200354A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh New heteroaryl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
KR20140050029A (en) * 2011-07-06 2014-04-28 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
JP2014529293A (en) 2011-07-08 2014-11-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Relaxin-releasing fusion protein and use thereof
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
DE102011082041A1 (en) 2011-09-02 2013-03-07 Bayer Pharma AG New substituted fused pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases
DE102012200351A1 (en) 2012-01-11 2013-07-11 Bayer Pharma Aktiengesellschaft New substituted annellated pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases
CN104039784B (en) 2011-09-02 2017-08-22 拜耳知识产权有限责任公司 Substituted cyclopyrimidines and uses thereof
PE20142359A1 (en) * 2011-11-25 2015-01-09 Bayer Pharma AG PROCEDURE FOR THE PREPARATION OF 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUTED
CN102491974B (en) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride
DE102012200349A1 (en) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
DE102012200352A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted, fused imidazoles and pyrazoles and their use
DE102012200360A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted triazines and their use
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
ES2561353T3 (en) 2012-01-13 2016-02-25 Novartis Ag Sales of an IP receiver agonist
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AR089698A1 (en) 2012-01-13 2014-09-10 Novartis Ag ANTAGONIST HETEROCICLIC COMPOUNDS OF THE IP RECEIVER
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2644781T3 (en) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabicycles substituted and their use
WO2013144191A1 (en) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases
US9290440B2 (en) 2012-04-16 2016-03-22 Toa Eiyo Ltd. Bicyclic compound
UA112897C2 (en) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт BICYCLIC SUBSTITUTED URATILES AND THEIR APPLICATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES
DE102012208530A1 (en) 2012-05-22 2013-11-28 Bayer Pharma AG Substituted piperidinoacetamides and their use
KR102137517B1 (en) 2012-07-20 2020-07-24 바이엘 파마 악티엔게젤샤프트 Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
ES2603262T3 (en) 2012-07-20 2017-02-24 Bayer Pharma Aktiengesellschaft Substituted aminoindane-carboxylic and aminotetralin-carboxylic acids and their use
WO2014058441A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
CA2891976C (en) 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
ES2637719T3 (en) 2013-02-13 2017-10-16 Novartis Ag IP receptor agonist heterocyclic compounds
CN105102457A (en) * 2013-02-21 2015-11-25 阿德弗里奥药品有限责任公司 {4,6-Diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate ester form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1216890A1 (en) * 2013-03-01 2016-12-09 Bayer Pharma Aktiengesellschaft Benzyl-substituted pyrazolopyridines and use thereof
WO2014131760A1 (en) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituted ring-fused pyrimidines and use thereof
SI2970243T1 (en) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. Sgc stimulators
CA2914040A1 (en) * 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
AU2014289312A1 (en) 2013-07-10 2016-02-11 Bayer Pharma Aktiengesellschaft Benzyl-1H-pyrazolo(3,4-b)pyridines and use thereof
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
US9422285B2 (en) * 2013-08-08 2016-08-23 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof
US20160221965A1 (en) 2013-09-16 2016-08-04 Bayer Pharma Aktiengesellschaft Disubstituted trifluoromethyl pyrimidinones and their use
CN105793267B (en) 2013-10-07 2018-02-06 拜耳制药股份公司 Cyclic thienouracil carboxamides and uses thereof
WO2015056663A1 (en) 2013-10-15 2015-04-23 トーアエイヨー株式会社 4-aminomethylbenzoic acid derivative
CN104327107A (en) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 A kind of preparation method of fluoroquinolone antibiotics
EP3062780A1 (en) 2013-11-01 2016-09-07 Bergen Teknologioverføring AS Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
HK1224288A1 (en) 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
CN105980381A (en) 2013-11-08 2016-09-28 拜耳医药股份有限公司 Substituted uracils and use thereof
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2016540017A (en) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulating substance
SG11201604949XA (en) 2013-12-19 2016-07-28 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines
WO2015091420A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
AP2016009276A0 (en) 2013-12-19 2016-06-30 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
CN106029648A (en) 2013-12-19 2016-10-12 拜耳制药股份公司 Substituted bipiperidinyl derivatives as adrenergic receptor α2C antagonists
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US9688699B2 (en) 2014-02-19 2017-06-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
KR20160145780A (en) 2014-04-24 2016-12-20 노파르티스 아게 Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (en) 2014-04-24 2016-12-09 노파르티스 아게 Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
HRP20201800T1 (en) 2014-08-01 2020-12-25 Bayer Pharma Aktiengesellschaft METHOD FOR PREPARING (4S) -4- (4-CYANO-2-METHOXYPHENYL) -5-ETOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND ITS PURIFICATION FOR USE AS ACTIVE PHARMACEUTICAL INGREDIENT
US20170233413A1 (en) 2014-08-29 2017-08-17 Bayer Pharma Aktiengesellschaft Substituted annulated pyrimidines and use thereof
CN107074883A (en) 2014-08-29 2017-08-18 拜耳医药股份有限公司 Cyclic pyrimidin of amino substitution and application thereof
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
UA121558C2 (en) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт HYDROXYALKYL-SUPTITUTED PHENYLTRIAZOLE DERIVATIVES AND THEIR APPLICATIONS
CN104374861B (en) * 2014-11-10 2016-03-02 广东东阳光药业有限公司 The method of the related substance of the western croak bulk drug of a kind of HPLC separation determination Leo
CN104434845B (en) * 2014-11-12 2017-12-05 广东东阳光药业有限公司 A kind of solid pharmaceutical preparation for including the western croak of Leo
TW201625635A (en) 2014-11-21 2016-07-16 默沙東藥廠 Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10292970B2 (en) 2014-12-02 2019-05-21 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
CN105777743A (en) * 2014-12-19 2016-07-20 奥浦顿（上海）医药科技有限公司 Preparation method and application of pyrazolo[3, 4-b]pyridine compound intermediate
CN104530044B (en) * 2014-12-31 2016-07-13 安徽联创生物医药股份有限公司 A kind of synthetic method of the western croak of Leo
WO2016113205A1 (en) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituted pentafluoroethyl pyrimidinones and use thereof
WO2016113415A1 (en) 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
UY36586A (en) 2015-03-26 2016-10-31 Bayer Pharma AG HETEROCICLILMETILTIENOURACILOS AND USE OF THE SAME
CN107580495A (en) 2015-05-06 2018-01-12 拜耳制药股份公司 The sGC stimulants, the sGC activators that combine individually and with PDE5 inhibitor are used for the purposes for treating the finger ulcer (DU) of adjoint system sclerosis (SSc)
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017013010A1 (en) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
PL3337800T3 (en) 2015-08-21 2019-10-31 Bayer Pharma AG Method for the production of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and its purification for use as an active pharmaceutical ingredient
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2017097792A1 (en) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
US10414765B2 (en) 2015-12-10 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
CN105461715B (en) * 2015-12-15 2017-03-29 郑州大明药物科技有限公司 A kind of synthetic method of the western croak intermediate of Leo
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121700A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase
WO2017121693A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituted thiazole and thiadiazole amides, and use thereof
WO2017121692A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituted sulfamides and use of same
WO2017153231A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof
WO2017153234A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof
WO2017153235A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-3-aryl-1-naphthamides and use thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
JP6911052B2 (en) 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト Oxoalkyl-substituted phenyltriazole derivatives and their use
JOP20170104A1 (en) 2016-05-03 2017-11-03 Bayer Pharma AG Amid-substituted phenyltriazole derivatives and their uses
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
WO2017191112A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
JOP20170113B1 (en) 2016-05-09 2023-03-28 Bayer Pharma AG Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
MX389964B (en) 2016-07-07 2025-03-19 Cyclerion Therapeutics Inc SOLID FORMS OF A SOLUBLE GUANYLATE CYCLASE STIMULATOR (SGC).
CN109476686B (en) 2016-07-07 2022-01-18 赛克里翁治疗有限公司 Phosphorus prodrugs of sGC stimulators
CN109689654A (en) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-Substituted 1-pyridyl-naphthyridine-3-carboxamides and their uses
JOP20190005A1 (en) * 2016-07-20 2019-01-20 Bayer Ag Substituted diazahetero-bicyclic compounds and their use
WO2018041771A1 (en) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituted thienouraciles and use thereof
CR20220309A (en) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc SGC STIMULATORS
JOP20190045A1 (en) 2016-09-14 2019-03-14 Bayer Ag Amide-1-aryl-naphthridine-3-carboxylic acid amide compounds are substituted at position 7 and used.
EP3296298A1 (en) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituted 1-aryl-naphthyridin-3-carboxamides and their use
WO2018054846A1 (en) 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N3-cyclically substituted thienouraciles and use thereof
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
JOP20190080A1 (en) 2016-10-14 2019-04-11 Bayer Pharma AG Compounds derived from 6-(1H-pyrazole-1-yl)pyrimidine-4-amine substituted and their uses
CN107964011A (en) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 Substituted pyrazolopyridines analog derivative and its medical usage
EP3529244A1 (en) 2016-10-20 2019-08-28 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
US11180493B2 (en) * 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
EA201991147A1 (en) 2016-11-08 2019-11-29 TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM USING sGC STIMULANTS
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EA202192558A1 (en) * 2016-12-14 2021-12-07 Байер Акциенгезельшафт SUBSTITUTED DIAZHETEROBICYCLIC COMPOUNDS AND THEIR APPLICATIONS
JOP20190141A1 (en) 2016-12-21 2019-06-12 Bayer Pharma AG Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
EP3338764A1 (en) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders
EP3338803A1 (en) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders
JOP20190148A1 (en) 2016-12-21 2019-06-18 Bayer Pharma AG Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
WO2018130226A1 (en) * 2017-01-16 2018-07-19 苏州科睿思制药有限公司 New crystal form of riociguat, preparation method and use thereof
CN110637027B (en) 2017-02-08 2024-08-30 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
WO2018153899A1 (en) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators
EP3609869A1 (en) 2017-04-10 2020-02-19 Bayer Aktiengesellschaft Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (en) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
CN108690016B (en) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 Pyrazolopyridine compounds and their uses
JP7090639B2 (en) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Fluoride-substituted indazole compounds and their use
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (en) 2017-06-14 2019-12-11 Bayer Pharma AG Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CU20200041A7 (en) 2017-10-24 2021-03-11 Bayer Ag SUBSTITUTE IMIDAZOPYRIDINE AMIDES
US20210253557A1 (en) 2017-10-24 2021-08-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
US11149023B2 (en) 2017-10-24 2021-10-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
CR20200176A (en) 2017-10-24 2020-07-24 Bayer Pharma AG Prodrugs of substituted triazole derivatives and uses thereof
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
CA3081775A1 (en) 2017-11-07 2019-05-16 Bayer Aktiengesellschaft Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same
WO2019105881A1 (en) 2017-12-01 2019-06-06 Bayer Pharma Aktiengesellschaft Method for producing (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient
CA3086207A1 (en) * 2017-12-19 2019-06-27 Cyclerion Therapeutics, Inc. Sgc stimulators
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
JP7314173B2 (en) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト Use of sGC activators and sGC stimulants for the treatment of cognitive impairment
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CR20200554A (en) 2018-05-17 2021-01-12 Bayer Ag Substituted dihydropyrazolo pyrazine carboxamide derivatives
CN110511219B (en) 2018-05-22 2022-06-03 年衍药业(珠海)有限公司 Phenyl-substituted dihydronaphthyridine compound and application thereof
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
KR20210031931A (en) 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. Use of sGC stimulants for the treatment of mitochondrial disorders
JP2021531297A (en) 2018-07-24 2021-11-18 バイエル・アクチエンゲゼルシヤフト Pharmaceutical dosage form that can be administered orally and has a modified release
CA3107169A1 (en) 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Pharmaceutical dosage form which can be administered orally and has modified release
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
PE20211285A1 (en) 2018-11-27 2021-07-19 Bayer Ag PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL FORMS CONTAINING INHIBITORS OF THE TASK-1 AND TASK-3 CHANNELS AND THEIR USE FOR THE THERAPY OF RESPIRATORY DISORDERS
WO2020109354A1 (en) 2018-11-28 2020-06-04 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020165031A1 (en) 2019-02-15 2020-08-20 Bayer Aktiengesellschaft Substituted isoquinoline-piperidinylmethanone derivatives
WO2020216669A1 (en) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenyl-substituted imidazopyridine amides and use thereof
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2020245342A1 (en) 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
CA3160035A1 (en) 2019-11-06 2021-05-14 Bayer Aktiengesellschaft Inhibitors of adrenoreceptor adrac2
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
EP4106741A1 (en) 2020-02-21 2022-12-28 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
EP4110396A1 (en) 2020-02-26 2023-01-04 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
WO2021202546A1 (en) 2020-03-31 2021-10-07 Cyclerion Therapeutics, Inc. Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2022057836A1 (en) * 2020-09-16 2022-03-24 南京明德新药研发有限公司 Benzourea ring derivative, and preparation method therefor and use thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4240750A1 (en) 2020-11-04 2023-09-13 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4259617B1 (en) 2020-12-10 2024-10-23 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN116829545A (en) 2020-12-10 2023-09-29 拜耳公司 Substituted pyrazolylpiperidinecarboxylic acid
JP7458683B2 (en) 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト Use of sGC activators for the treatment of ophthalmological diseases
EP4326722A1 (en) 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Sgc stimulators
TW202308634A (en) 2021-04-20 2023-03-01 美商賽克瑞恩醫療公司 Treatment of cns diseases with sgc stimulators
CN117279923B (en) * 2021-04-27 2025-09-30 南京明德新药研发有限公司 Derivatives of six-membered heteroaromatic urea rings and their applications
WO2022265984A1 (en) 2021-06-14 2022-12-22 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
WO2023018795A1 (en) 2021-08-11 2023-02-16 Curtails Llc Nep inhibitors for the treatment of laminitis
TW202342012A (en) 2021-12-29 2023-11-01 德商拜耳廠股份有限公司 Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound
US20250281480A1 (en) 2021-12-29 2025-09-11 Bayer Aktiengesellschaft Pharmaceutical dry powder inhalation formulation
CN118765199A (en) 2021-12-29 2024-10-11 拜耳股份公司 Treatment of cardiopulmonary diseases
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc Oral formulations of levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
CN115947689B (en) * 2022-09-23 2025-08-29 湖南华腾制药有限公司 A method for synthesizing riociguat intermediates using a continuous flow microreactor
CN120225524A (en) 2022-10-18 2025-06-27 帝善多制药公司 Pyrimidine sGC stimulators
EP4605080A1 (en) 2022-10-18 2025-08-27 Tisento Therapeutics Inc. Treatment of mitochondrial diseases with sgc stimulators
AR133983A1 (en) 2023-09-28 2025-11-19 Bayer Ag SUBSTITUTED HETEROCYCLIC CARBOXAMIDES AND THEIR USE
CN117924280B (en) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 Substituted thienyl-5-fluoro-1H-pyrazolopyridine compound and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
IL129416A0 (en) 1996-10-14 2000-02-17 Bayer Ag New heterocyclylmethyl-substituted pyrazol derivatives
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
DE19649460A1 (en) 1996-11-26 1998-05-28 Bayer Ag New substituted pyrazole derivatives
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19834045A1 (en) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
DE19834044A1 (en) * 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19846514A1 (en) * 1998-10-09 2000-04-20 Bayer Ag New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
AR031176A1 (en) * 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10057754A1 (en) * 2000-11-22 2002-05-23 Bayer Ag New cyclic sulfonamido-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10057751A1 (en) 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
JP4295505B2 (en) 2000-11-22 2009-07-15 バイエル アクチェンゲゼルシャフト New lactam substituted pyrazolopyridine derivatives
DE10122894A1 (en) * 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE10132416A1 (en) 2001-07-04 2003-01-16 Bayer Ag New morpholine-bridged pyrazolopyridine derivatives
DE10350148B3 (en) 2003-10-28 2005-02-10 Daimlerchrysler Ag Bank for vehicle seat has a ventilation shafts connected by aperture in rear wall with surrounding air

Also Published As

Publication number Publication date
LU92419I2 (en) 2014-06-02
EP1506193B1 (en) 2006-06-21
HRP20041166B1 (en) 2013-05-31
IL164958A (en) 2010-05-17
PT1506193E (en) 2006-10-31
LTPA2014018I1 (en) 2014-05-26
AR039789A1 (en) 2005-03-02
NL300659I2 (en) 2017-02-02
JP2005531553A (en) 2005-10-20
CU23453B7 (en) 2009-12-01
SI1506193T1 (en) 2006-12-31
FR14C0032I2 (en) 2014-11-21
NZ536417A (en) 2006-08-31
BR0309855A (en) 2005-03-01
MY136841A (en) 2008-11-28
ATE330957T1 (en) 2006-07-15
ES2268363T3 (en) 2007-03-16
RU2339638C2 (en) 2008-11-27
CY2014018I2 (en) 2015-12-09
UA78314C2 (en) 2007-03-15
RU2339638C9 (en) 2009-09-20
TW200404797A (en) 2004-04-01
NO2025058I1 (en) 2025-12-12
FR14C0032I1 (en) 2014-05-16
PL214985B1 (en) 2013-10-31
RU2004136277A (en) 2005-06-27
CA2485143A1 (en) 2003-11-20
NO2014018I2 (en) 2015-08-31
CY2014018I1 (en) 2015-12-09
CN1330649C (en) 2007-08-08
AU2003233061A1 (en) 2003-11-11
CY1105579T1 (en) 2010-07-28
DE50303960D1 (en) 2006-08-03
ECSP045414A (en) 2005-01-03
US20060052397A1 (en) 2006-03-09
KR101011864B1 (en) 2011-02-01
MXPA04011003A (en) 2005-02-14
IL164958A0 (en) 2005-12-18
HRP20041166A2 (en) 2005-08-31
TWI282792B (en) 2007-06-21
PL373336A1 (en) 2005-08-22
WO2003095451A1 (en) 2003-11-20
LTC1506193I2 (en) 2026-03-25
GT200300101A (en) 2004-03-08
EP1506193A1 (en) 2005-02-16
NO2014018I1 (en) 2014-07-18
NO20045277L (en) 2004-12-01
EP1506193B9 (en) 2026-02-18
DK1506193T3 (en) 2006-10-09
BRPI0309855B1 (en) 2018-10-16
DOP2003000639A (en) 2003-11-15
EP1506193B3 (en) 2025-12-03
HK1082247A1 (en) 2006-06-02
KR20050003415A (en) 2005-01-10
CN1665811A (en) 2005-09-07
SI1506193T2 (en) 2026-03-31
ZA200408925B (en) 2006-01-25
JP4455321B2 (en) 2010-04-21
BRPI0309855B8 (en) 2021-05-25
US7173037B2 (en) 2007-02-06
FI1506193T6 (en) 2026-03-03
NO329105B1 (en) 2010-08-23
CA2485143C (en) 2011-04-19
UY27793A1 (en) 2003-12-31
DK1506193T6 (en) 2026-03-02
DE10220570A1 (en) 2003-11-20
PE20040197A1 (en) 2004-04-22
AU2003233061B2 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
BE2019C510I2 (en)
BE2018C021I2 (en)
BE2017C049I2 (en)
BE2016C069I2 (en)
BE2016C040I2 (en)
BE2016C013I2 (en)
BE2015C078I2 (en)
BE2016C002I2 (en)
BE2018C018I2 (en)
BE2015C017I2 (en)
BE2014C053I2 (en)
BE2014C051I2 (en)
BE2014C041I2 (en)
BE2014C030I2 (en)
BE2014C016I2 (en)
BE2014C015I2 (en)
BE2013C063I2 (en)
BE2013C039I2 (en)
BE2011C038I2 (en)
JP2003199143A5 (en)
BE2015C069I2 (en)
BE2013C046I2 (en)
AU2001278584A1 (en)
AU2002233037A1 (en)
AU2002227782A1 (en)